www.hepatology-druginteractions.org			UNIVERSITY OF LIVERPOOL
		Interaction Report	
Report ID: Date Produced:	05 October 2024		
Hepatology Treatmen	t	Co-medications	

Sofosbuvir/Velpatasvir

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Methotrexate

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown. Please note that some co-medications with a green classification may require dose adjustment due to hepatic impairment.

For full details of all interactions, see www.hepatology-druginteractions.org.

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Sofosbuvir/Velpatasvir + Methotrexate

Coadministration has not been studied. Methotrexate is a substrate of BCRP and concentrations may increase due to inhibition by sofosbuvir/velpatasvir. Although no a priori dose alteration is required, close monitoring is recommended.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

The specific planet provided for information only, it is not intended to replace a possibility of an account planet provided to information only, it is not intended to replace a possibility of an account planet provided to information only. The specific planet provided for information only, it is not intended to replace a possibility of an account planet provided to information only. It is not intended to replace a possibility of an account planet provided to information only and account planet provided to replace a possibility of an account planet planet